Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2016

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study

Mohamad Mohty
  • Fonction : Auteur
  • PersonId : 953688
Pierre-Yves Dumas
  • Fonction : Auteur
  • PersonId : 931756
Gabriel Etienne
Bruno Royer
  • Fonction : Auteur
Dominique Bordessoule
  • Fonction : Auteur
  • PersonId : 833217
Stephanie Nguyen

Résumé

Intravascular hemolysis in Paroxysmal nocturnal hemoglobinuria (PNH) can effectively be controlled with eculizumab, a humanized monoclonal antibody that binds complement protein C5. We report here a retrospective comparison study between 123 patients treated with eculizumab in the recent period (>2005) and 191 historical controls (from the French registry). Overall survival (OS) at 6 years was 92% (95%CI, 87 to 98) in the eculizumab cohort versus 80% (95%CI 70 to 91) in historical controls diagnosed after 1985 (HR 0.38 [0.15 to 0.94], P = 0.037). There were significantly fewer thrombotic events (TEs) in the group of patients treated with eculizumab (4% [1-10]) as compared to the historical cohort (27% [20-34]). However, we found that TEs may still occur after the initiation of eculizumab treatment and that previous TEs still have a negative impact on survival. Evolutions to myelodysplastic syndrome or acute leukemia were similar in both cohorts. There was less evolution to aplastic anemia in the treatment group. In multivariate analysis, absence of a previous TE and treatment with eculizumab were associated with a better OS. Treatment with eculizumab improves overall survival in classic PNH patients without increasing the risk of clonal evolution.

Dates et versions

hal-01885662 , version 1 (02-10-2018)

Identifiants

Citer

Louis Loschi, Raphaël Porcher, Fiorenza Barraco, Louis Terriou, Mohamad Mohty, et al.. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. American Journal of Hematology, 2016, 91 (4), pp.366 - 370. ⟨10.1002/ajh.24278⟩. ⟨hal-01885662⟩
214 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More